

10/535220

JC20 Rec'd PCT/PTO 17 MAY 2005

932.1303

UNITED STATES PATENT AND TRADEMARK OFFICE

Re: Application of: Juan Carlos DOMINGO PEDROL et al.
Serial No.: Not yet known
Filed: Herewith
For: USE OF DOCOSAHEXANOIC ACID AS
ACTIVE SUBSTANCE FOR THE TREATMENT
OF LIPODYSTROPHY

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

May 17, 2005

Dear Sir:

Pursuant to M.P.E.P. §609 and 37 C.F.R. §§1.56, 1.97-1.99, applicant submits herewith an information disclosure citation which lists references of which the applicant is aware. A copy of each of the references is also submitted herewith.

An English translation of DE 40 17 979 is not available at this time. However, an English-language abstract of this reference is submitted herewith. It is respectfully submitted that the relevance of this reference can be readily understood by referring to the drawings of the patent and corresponding English-language abstract provided.

An English translation of FR 2 749 133 is not available at this time. It is respectfully submitted that the relevance of this reference can be readily understood by referring to the drawings of the patent provided.

An English translation of EP 0 378 824 is not available at this time. It is respectfully submitted that the relevance of this reference can be readily understood by referring to the drawings of the patent provided.

This submission does not represent that a search has been made or that no better art exists. While the term "references" is used in citing the publications called to the examiner's attention herein, applicants do not make any admission that each or all of them are "prior art" references within the meaning of the statutory and case law.

Applicant reserves the right to contend, where appropriate, that a reference asserted against any claim of the present application is not prior art under the facts and the law.

Applicant also reserves the right to present appropriate arguments and/or evidence to establish patentability over the references, should one or more of the references be applied against the claims of the present application.

Applicant respectfully requests that the examiner independently determine those items which the examiner would consider the most pertinent of all the references cited herein.


Applicant respectfully requests that the references be considered and made of record.

10/535220

JC20 Rec'd PCT/PTO 17 MAY 2005

This Information Disclosure Statement is being filed simultaneously with the filing of the application and therefore no fee is due. However, in the event that a fee is required, the Director is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 500518.

Respectfully submitted,

By: 
Dona C. Edwards
Reg. No. 42,507

Encls. PTO-1449
4 References
International Search Report

Steinberg & Raskin, P.C.
1140 Avenue of the Americas, 15th Floor
New York, NY 10036-5803
Telephone: (212) 768-3800
Facsimile: (212) 382-2124
E-mail: pto@steinbergraskin.com

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 932.1303		SERIAL NO.: Not yet known 107535220				
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Juan Carlos DOMINGO PEDROL						
				FILING DATE: Herewith		GROUP: Not yet known				
U.S. PATENT DOCUMENTS										
*EXAMINER INITIAL		DOCUMENT NUMBER			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
AA										
AB										
AC										
AD										
AE										
AF										
AG										
AH										
AI										
AJ										
AK										
FOREIGN PATENT DOCUMENTS										
		DOCUMENT NUMBER			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
									YES	NO
AL	2	7	4	9	1	3	3			X
AM	4	0	1	7	9	7	9			Abstract
AN	0	3	7	8	8	2	4			X
AO										
AP										
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)										
	AQ	Bégin, M.E. "Plasma Fatty Acid Levels in Patients with Acquired Immune Deficiency Syndrome and in Controls". Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 37, no. 2, - August 1989 (1989-08) pages 135-137.								
	AR									
	AS									
EXAMINER						DATE CONSIDERED				
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>										